• Je něco špatně v tomto záznamu ?

Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries

CI. Busard, AD. Cohen, P. Wolf, S. Gkalpakiotis, S. Cazzaniga, RS. Stern, BA. Hutten, I. Feldhamer, F. Quehenberger, R. Lichem, M. Kojanova, E. Adenubiova, A. Addis, L. Naldi, PI. Spuls,

. 2018 ; 32 (2) : 245-253. [pub] 20171017

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033730

BACKGROUND: Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes. OBJECTIVE: To describe the use of combined treatment of biologics with conventional systemic agents or phototherapy in daily clinical practice. METHODS: We collected data on frequency of use, demographics, treatment characteristics and drug survival of biologics combined with conventional systemic agents or phototherapy in five PSONET registries. RESULTS: Of 9922 biologic treatment cycles, 982 (9.9%) were identified as combination treatment. 72.9% of treatment cycles concerned concomitant use of methotrexate, 25.3% concerned concomitant UVB therapy, acitretin or cyclosporin and 1.8% concerned combined treatment with PUVA, fumaric acids or a second biologic. Substantial variation was detected in type and frequency of combination treatments prescribed across registries. Patients initiated on combined treatment had generally severe disease and were affected with psoriasis for many years. The extent to which patients had been priory treated with biologic monotherapy and the proportion of patients affected with psoriatic arthritis differed between registries. Survival rates for etanercept, adalimumab, infliximab and ustekinumab with methotrexate ranged between 43 and 92%, 28 and 83%, 65 and 87% and 53 and 77%, respectively, across registries after one year with no consistent superior survival for a particular biologic. Longest survival on a biologic combined with methotrexate, acitretin or cyclosporin was 103, 78 and 34 months, respectively. CONCLUSION: Methotrexate was the most commonly used concomitant treatment for patients on a biologic. Wide geographical variations in treatment selection and persistence of combination treatment exist. Data derived from ongoing studies may help to determine whether combined treatment is superior to biologic monotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033730
003      
CZ-PrNML
005      
20181015124227.0
007      
ta
008      
181008s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jdv.14583 $2 doi
035    __
$a (PubMed)28898541
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Busard, C I $u Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
245    10
$a Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries / $c CI. Busard, AD. Cohen, P. Wolf, S. Gkalpakiotis, S. Cazzaniga, RS. Stern, BA. Hutten, I. Feldhamer, F. Quehenberger, R. Lichem, M. Kojanova, E. Adenubiova, A. Addis, L. Naldi, PI. Spuls,
520    9_
$a BACKGROUND: Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes. OBJECTIVE: To describe the use of combined treatment of biologics with conventional systemic agents or phototherapy in daily clinical practice. METHODS: We collected data on frequency of use, demographics, treatment characteristics and drug survival of biologics combined with conventional systemic agents or phototherapy in five PSONET registries. RESULTS: Of 9922 biologic treatment cycles, 982 (9.9%) were identified as combination treatment. 72.9% of treatment cycles concerned concomitant use of methotrexate, 25.3% concerned concomitant UVB therapy, acitretin or cyclosporin and 1.8% concerned combined treatment with PUVA, fumaric acids or a second biologic. Substantial variation was detected in type and frequency of combination treatments prescribed across registries. Patients initiated on combined treatment had generally severe disease and were affected with psoriasis for many years. The extent to which patients had been priory treated with biologic monotherapy and the proportion of patients affected with psoriatic arthritis differed between registries. Survival rates for etanercept, adalimumab, infliximab and ustekinumab with methotrexate ranged between 43 and 92%, 28 and 83%, 65 and 87% and 53 and 77%, respectively, across registries after one year with no consistent superior survival for a particular biologic. Longest survival on a biologic combined with methotrexate, acitretin or cyclosporin was 103, 78 and 34 months, respectively. CONCLUSION: Methotrexate was the most commonly used concomitant treatment for patients on a biologic. Wide geographical variations in treatment selection and persistence of combination treatment exist. Data derived from ongoing studies may help to determine whether combined treatment is superior to biologic monotherapy.
650    _2
$a acitretin $x terapeutické užití $7 D017255
650    _2
$a adalimumab $x terapeutické užití $7 D000068879
650    _2
$a Rakousko $7 D001317
650    _2
$a biologické přípravky $x terapeutické užití $7 D001688
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a cyklosporin $x terapeutické užití $7 D016572
650    _2
$a Česká republika $7 D018153
650    _2
$a dermatologické látky $x terapeutické užití $7 D003879
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a etanercept $x terapeutické užití $7 D000068800
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fumaráty $x terapeutické užití $7 D005650
650    _2
$a lidé $7 D006801
650    _2
$a infliximab $x terapeutické užití $7 D000069285
650    _2
$a Izrael $7 D007557
650    _2
$a Itálie $7 D007558
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x terapeutické užití $7 D008727
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Nizozemsko $7 D009426
650    12
$a PUVA terapie $7 D011701
650    _2
$a psoriáza $x terapie $7 D011565
650    _2
$a registrace $7 D012042
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a ustekinumab $x terapeutické užití $7 D000069549
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cohen, A D $u Department of Quality Measurements and Research, Clalit Health Services, Tel-Aviv, Israel.
700    1_
$a Wolf, P $u Department of Dermatology, Medical University of Graz, Graz, Austria.
700    1_
$a Gkalpakiotis, S $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Cazzaniga, S $u Centro Studi GISED, Fondazione per la Ricerca, Ospedale Maggiore, Bergamo, Italy. Dermatology Department, Inselspital University Hospital, Bern, Switzerland.
700    1_
$a Stern, R S $u Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
700    1_
$a Hutten, B A $u Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Feldhamer, I $u Department of Quality Measurements and Research, Clalit Health Services, Tel-Aviv, Israel.
700    1_
$a Quehenberger, F $u Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
700    1_
$a Lichem, R $u Department of Dermatology, Medical University of Graz, Graz, Austria.
700    1_
$a Kojanova, M $u Department of Dermatovenereology, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
700    1_
$a Adenubiova, E $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Addis, A $u Department of Epidemiology, Servizio Sanitario Regionale, Regione Lazio, Italy.
700    1_
$a Naldi, L $u Centro Studi GISED, Fondazione per la Ricerca, Ospedale Maggiore, Bergamo, Italy.
700    1_
$a Spuls, P I $u Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
773    0_
$w MED00002983 $t Journal of the European Academy of Dermatology and Venereology JEADV $x 1468-3083 $g Roč. 32, č. 2 (2018), s. 245-253
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28898541 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181015124723 $b ABA008
999    __
$a ok $b bmc $g 1340270 $s 1030724
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 32 $c 2 $d 245-253 $e 20171017 $i 1468-3083 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venerol $x MED00002983
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace